Biomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
Vienna, November 13, 2023
Biomay expanded its biomanufacturing facility in central Vienna, 9th district, by adding clean rooms, laboratories, and warehouse premises in the Vienna Competence Center building. Besides the 4000 sqm main site in Vienna 22nd district, Biomay now operates an additional 2000 sqm integrated biomanufacturing facility, equipped with five GMP-commissioned clean rooms for upstream and downstream processing and aseptic filling. Furthermore, the site features comprehensive laboratories for quality control, process and assay development.
A New Center of Excellence for mRNA
The upgraded site will serve as Biomay's Center of Excellence for end-to-end Contract Development and Manufacturing Organization (CDMO) services, specifically for messenger RNA (mRNA) manufacturing. The GMP service offerings for mRNA include plasmid cell banking, circular plasmid and linear DNA template manufacturing, in-vitro transcription (IVT) of mRNA drug substance, and aseptic filling of mRNA drug product. Biomay employs cutting-edge enzymatic run-off transcription based on linear DNA templates for mRNA processing, offering various options for 5´-capping, 3´-poly-adenylation, and nucleotide modification as per client requirements.
Notably, Biomay has a strong track record in GMP production of linear DNA templates, supplying significant amounts of these templates during the COVID-19 pandemic for the manufacturing of a COVID-19 mRNA vaccine. The company has also gained extensive experience in GMP manufacturing of DNA templates for other clinical indications, such as oncology.
Aseptic Filling Capacities
Biomay's aseptic filling capacities include a seven-glove isolator equipped with an automated processing line for aseptic filling, vial capping and crimping, primarily serving clinical-stage investigational medicinal products (IMPs). Dr. Angela Neubauer, the Site Head of the facility and Biomay's Senior Vice President Client Business, emphasized the company's evolution from being a drug substance and API manufacturer to offering drug product aseptic filling, testing and release services. She highlighted Biomay's strategic goal of establishing itself as a leading player in the mRNA CDMO field, alongside its existing expertise in proteins and plasmids.
Contacts
Dr. Angela NeubauerSVP Client BusinessBiomay AG
Ada Lovelace-Str. 2
A-1220 Vienna, Austria
Images
Links
About Biomay
Founded in 1984, Biomay AG is a fully integrated CDMO with a focus on microbial based GMP services for manufacturing therapeutic proteins, plasmid DNA and mRNA. The new site complements Biomay’s main manufacturing site in Vienna Seestadt (22nd district, Ada Lovelace-Strasse), established in 2021.
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
HEIDELBERG/Amperfied presents new DC fast charging solution with comprehensive range of services: Focus on dynamic power distribution and high availability7.5.2025 08:56:00 CEST | Press release
Offer is aimed at the increasing demand from charging parks, logistics depots and haulage fleets Amperfied addresses demand for fast charging system solutions with new DC product and performance-based offering DC becomes part of an availability-based operating hours model Modular technology for optimum utilization of the charging system and small footprint Debut at the Power2Drive 2025 Amperfied GmbH, a subsidiary of Heidelberger Druckmaschinen AG (HEIDELBERG), is entering the market for fast charging solutions complete with a comprehensive range of services. At the Power2Drive trade fair in Munich, the company will unveil its modular DC fast charging solution called Amperfied Dynamic DC, which focuses on availability and efficiency. The offering is aimed primarily at the growing demand from charging parks, logistics depots and haulage fleets for high-availability system solutions. This is because only with fast and functional charge points can charging infrastructure operators (CPOs)
HEIDELBERG holds its ground in a difficult market environment in FY 2024/25 - targets achieved, significant increase in incoming orders compared to previous year6.5.2025 08:52:59 CEST | Press release
Sales and adjusted EBITDA margin at previous year's level according to preliminary figures Free cash flow excluding special items clearly positive at around € 50 million Rising order intake compared to previous year lays the foundation for a good start to FY 2025/26 Additional, positive order impetus expected from China Print trade fair in May Adjusted EBITDA margin to rise to around 8 percent in FY 2025/26
eM Client version 10.3 adds features familiar from Postbox5.5.2025 13:32:56 CEST | Press release
Prague – 05.05.2025 - The Czech company eM Client has launched a new version of its eponymous email application, positioning their software as the primary rival to Microsoft Outlook in the email app market. The most recent release, version 10.3, also incorporates the most popular features from Postbox, an email application developed by Postbox Inc., which has ceased operations and was acquired by eM Client in 2024.
TRENTAR MOBILITY GmbH enters the German market and acquires ORTEN Group – strategic partnership for future technologies and growth5.5.2025 10:30:00 CEST | Press release
ORTEN Group remains independent and will serve as TRENTAR MOBILITY’s growth platform in Europe Expansion of competencies in future mobility solutions, along with broader access to investments, markets, and technological expertise TRENTAR MOBILITY is exploring additional strategic growth opportunities and is interested in acquiring further manufacturers in Europe for growth in the future mobility sector
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom